Which university has the most Nobel Prize winners?

Harvard University leads with the most Nobel Prize winners among its affiliated researchers, followed by University of Cambridge, Stanford University, and MIT.

What is the Academinence prestige score?

The Academinence prestige score weights awards by their significance: Apex tier awards (Nobel, Fields Medal, Turing) receive 10 points, Elite tier awards (Wolf, Lasker, Shaw) receive 3 points, and Prestigious tier awards receive 1 point.

How many prestigious academic awards does Academinence track?

Academinence tracks over 100 prestigious academic awards across sciences, mathematics, medicine, economics, and engineering, including Nobel Prizes, Fields Medals, Turing Awards, Wolf Prizes, Breakthrough Prizes, Lasker Awards, and many more.

Allen Bard(1933)

Name: Academinence Academic Awards Database
Creator: Academinence
License: https://creativecommons.org/licenses/by/4.0/

Chemistry

Allen Bard is a recipient of the Wolf Prize in Chemistry (2008) from United States. Their primary field is Chemistry.

ORCID Wikipedia OpenAlex

United StatesThe University of Texas at Austin

Wolf Prize in Chemistry (2008)

Wikipedia ORCID

Major Awards

1,333

Publications

134,577

Citations

163

h-index

979

i10-index

101

Avg Citations/Paper

Awards & Recognition

Wolf Prize in Chemistry University of Texas at Austin

2008

Most Cited Works

Top publications by citation count

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Blood(2014)

citations

Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

Cancer(2008)

citations

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

Journal of Clinical Oncology(2006)

citations

The frequency of the JAK2 V617F mutation in patients with polycythemia vera and its correlation with severity of disease.

Journal of Clinical Oncology(2006)

citations

Troxacitabine administered by continuous infusion (CI) is well tolerated and effective in adults with relapsed or refractory acute myeloid leukemia (AML)

Journal of Clinical Oncology(2005)

citations

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Blood(2005)

citations

#10

Arsenic Trioxide (ATO) Is Safe and Effective in Combination with Low-Dose Ara-C (LDAC) for the Treatment of IPSS-2 Myelodysplastic Syndrome (MDS) and Poor-Prognosis Acute Myeloid Leukemia (AML) in Elderly Patients.

Blood(2005)

citations

Recent Publications

View all works

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Blood2014

4citations

Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

Cancer2008

50citations

Open Access

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

Journal of Clinical Oncology2006

21citations

Open Access

The frequency of the JAK2 V617F mutation in patients with polycythemia vera and its correlation with severity of disease.

Journal of Clinical Oncology2006

0citations

Troxacitabine administered by continuous infusion (CI) is well tolerated and effective in adults with relapsed or refractory acute myeloid leukemia (AML)

Journal of Clinical Oncology2005

2citations

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Blood2005

4citations

Arsenic Trioxide (ATO) Is Safe and Effective in Combination with Low-Dose Ara-C (LDAC) for the Treatment of IPSS-2 Myelodysplastic Syndrome (MDS) and Poor-Prognosis Acute Myeloid Leukemia (AML) in Elderly Patients.

Blood2005

5citations

External Profiles

ORCID

0000-0002-8517-0230

OpenAlex

Publications & Citations

Publications & Citations

Co-winners

Shared the same award in the same year

William E. Moerner

Wolf Prize in Chemistry (2008)

Top Publications

Probing Size and Substrate Effects on the Hydrogen Evolution Reaction by Single Isolated Pt Atoms, Atomic Clusters, and Nanoparticles

Journal of the American Chemical Society2019146 citations

A Study of the Mechanism of the Hydrogen Evolution Reaction on Nickel by Surface Interrogation Scanning Electrochemical Microscopy

Journal of the American Chemical Society2017142 citations

Electrodeposition of Isolated Platinum Atoms and Clusters on Bismuth—Characterization and Electrocatalysis

Journal of the American Chemical Society2017133 citations

Scanning electrochemical microscopy at the nanometer level

Chemical Communications2018126 citations

High-Performance Photodetectors Based on Solution-Processed Epitaxial Grown Hybrid Halide Perovskites

Nano Letters2018123 citations

Related Laureates

Other winners of the same award(s)

Samuel Danishefsky

Wolf Prize in Chemistry (2000)

Omar Yaghi

Nobel Prize in Chemistry (2025)

Helmut Schwarz

Wolf Prize in Chemistry (2025)

Robert Langer

Kavli Prize in Nanoscience (2024)

Carolyn R. Bertozzi

Priestley Medal (2023)

Bonnie L. Bassler

Gairdner International Award (2023)

Jeffery W. Kelly

Wolf Prize in Chemistry (2023)

Chuan He

Wolf Prize in Chemistry (2023)

Data Sources

Profile data aggregated from OpenAlex, Semantic Scholar, Wikidata, ORCID, and curated award records. Citation metrics may vary between sources.

Report a data error

Allen Bard(1933)

Awards & Recognition

Most Cited Works

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Implications of improved survival in patients with chronic myeloid leukemia: a nursing perspective

Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.

Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?

Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

The frequency of the JAK2 V617F mutation in patients with polycythemia vera and its correlation with severity of disease.

Troxacitabine administered by continuous infusion (CI) is well tolerated and effective in adults with relapsed or refractory acute myeloid leukemia (AML)

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Arsenic Trioxide (ATO) Is Safe and Effective in Combination with Low-Dose Ara-C (LDAC) for the Treatment of IPSS-2 Myelodysplastic Syndrome (MDS) and Poor-Prognosis Acute Myeloid Leukemia (AML) in Elderly Patients.

Recent Publications

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Implications of improved survival in patients with chronic myeloid leukemia: a nursing perspective

Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.

Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?

Arsenic trioxide and low‐dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.

The frequency of the JAK2 V617F mutation in patients with polycythemia vera and its correlation with severity of disease.

Troxacitabine administered by continuous infusion (CI) is well tolerated and effective in adults with relapsed or refractory acute myeloid leukemia (AML)

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Arsenic Trioxide (ATO) Is Safe and Effective in Combination with Low-Dose Ara-C (LDAC) for the Treatment of IPSS-2 Myelodysplastic Syndrome (MDS) and Poor-Prognosis Acute Myeloid Leukemia (AML) in Elderly Patients.

External Profiles

Co-winners

Top Publications

Related Laureates

Data Sources